Lunai Bioworks shares rise 61.05% in intraday after acquiring CNS drug assets from Clemann Group in a $20M deal.

Lunai Bioworks surged 61.05% in intraday trading, following its March 26 announcement to acquire the Clemann Group's blood-brain barrier delivery technology and CNS Alzheimer's drug assets for $20 million at $1.50 per share to address key bottlenecks in drug development; the company, focused on AI-driven discovery, diagnostics, and bio-defense across its RENB, BioSymetrics, and RENC divisions, operates as a preclinical biotech firm dedicated to precision medicine applications.